Abstract
Intro: Guidelines advise screening patients for latent TB infection (LTBI) prior to initiation of biologic therapy. We examined the impact of interferon gamma release assay (IGRA) availability on rates of adequate screening and treatment for LTBI prior to biologic therapy in a low TB incidence setting. Method: We analysed clinic letters, laboratory and pharmacy data to assess LTBI screening for patients starting biologics at a UK district general hospital between 2009-14. We used logistic regression to identify predictors of LTBI treatment. Results: 450 patients initiated biologics 2009-14: 116 before, and 334 after, IGRA availability (Jan 2010). 100/334 (30%) were IGRA tested. Adequate screening, defined as any immunological test and clinical review, increased with IGRA availability but remained low (105/334 vs 14/116; p Conclusion: LTBI screening in patients starting biologics improved after IGRA availability, but 69% were inadequately screened. Historically a negative IGRA has not influenced the decision to treat, but improved data on the negative predictive value of IGRAs may reduce treatment rates. In our limited sample, this did not adversely affect outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
